Compare Regeneron Pharmaceuticals Inc (REGN) vs SPDR Kensho Final Frontiers ETF (ROKT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs SPDR Kensho Final Frontiers ETF — how do they compare? Regeneron Pharmaceuticals Inc trades at $807.6 (market cap $83.43B), while SPDR Kensho Final Frontiers ETF trades at $106.56. The key difference: Regeneron Pharmaceuticals Inc pays a 0.46% dividend while SPDR Kensho Final Frontiers ETF pays none, and Regeneron Pharmaceuticals Inc is trading nearer its 52-week high, SPDR Kensho Final Frontiers ETF nearer its low. Which is the better fit depends on your goals.
| REGN | ROKT | |
|---|---|---|
Market Cap | $83.43B | — |
Sector | Health | Sector/Thematic |
52-Week High | $852.03 | $136.68 |
52-Week Low | $555.51 | $71.62 |
Enterprise Value | $78.14B | — |
Dividend Yield | 0.46% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.
Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About SPDR Kensho Final Frontiers ETF
SPDR Kensho Final Frontiers ETF seeks exposure to companies supporting exploration of outer space and the deep sea. Its holdings include businesses involved in aerospace, defense, communications, research, and related technologies.
Read more on ROKT →
